Investment Thesis
Tyra Biosciences is a pre-revenue biopharmaceutical company with a fortress balance sheet ($85M cash, minimal debt) but significant fundamental concerns including substantial operating losses (-$42M), negative cash flow (-$32.7M FCF), and deteriorating profitability trends YoY (-38.7%). Strong financial runway provides operational flexibility, but lacks revenue validation and shows accelerating cash burn.
Strengths
- Exceptional balance sheet strength with $85M cash and zero debt
- Minimal liabilities ($24.5M) relative to $412M asset base
- Extreme liquidity position (20.49x current ratio) supports extended R&D runway
- Significant stockholders equity ($387.6M) provides capital cushion
Risks
- Pre-revenue company with no commercial product validation or sales
- Operating cash burn of -$32.6M annually with only ~2.6 years runway at current burn rate
- Net losses deteriorating YoY (-38.7%), indicating spending acceleration without offsetting revenue growth
- Early-stage biopharma execution risk: clinical failures, regulatory delays, or financing challenges could deplete runway
- Insider activity (9 Form 4 filings/90 days) warrants monitoring for potential dilution or unresolved concerns
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway estimate
- Clinical trial progress, milestones, and regulatory approval timelines
- R&D efficiency metrics and cost per development milestone
- Quarterly cash balance and any financing activity (equity raises, debt issuance)
Financial Metrics
Revenue
N/A
Net Income
-39.3M
EPS (Diluted)
$-0.64
Free Cash Flow
-32.7M
Total Assets
412.0M
Cash
85.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.1%
ROA
-9.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
20.49x
Quick Ratio
20.49x
Debt/Equity
0.00x
Debt/Assets
5.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:32:44.404191 |
Data as of: 2026-03-31 |
Powered by Claude AI